A Randomized Phase II Induction Discontinuation Trial of Emactuzumab following Paclitaxel and Bevacizumab in Patients with platinum-resistant, epithelial ovarian, fallopian tube or primary peritoneal cancer

You are being asked to take part in this study because you have ovarian, Fallopian tube, or primary peritoneal cancer that is relapsed (has come back) or refractory (has not responded to treatment). The goal of this clinical research study is to learn if adding emactuzumab to the combination of paclitaxel and bevacizumab can help to control relapsed or refractory ovarian, Fallopian tube, or primary peritoneal cancer. The safety and side effects of this drug combination will also be studied.

Treatment Location: N/A

Sponsor: N/A

IRB Review and Approval Date: 05/05/2017

Recruitment Status: Closed

Projected Accrual: N/A

Phone Number: 1-877-MDA-6789

clinicaltrials.gov NCT No: NCT02923739